Drug Trial Radar · NCT02862535
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 20, 2026Latest source record: Dec 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
36
Actual
Start
Sep 20, 2016
Primary completion
Oct 25, 2019
Study completion Oct 25, 2019
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Aug 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to characterize the safety and tolerability of andecaliximab as monotherapy and in combination with anti-cancer agents in Japanese participants with inoperable advanced or recurrent gastric or recurrent gastroesophageal junction (GEJ) adenocarcinoma.
Conditions
- Gastric Adenocarcinoma
Interventions
AndecaliximabDrug
Administered via intravenous (IV) infusion (approximately 30 minutes)
S-1Drug
Administered orally
CisplatinDrug
Administered via IV infusion on Day 8 of every 5 weeks
OxaliplatinDrug
Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
NivolumabDrug
Administered via IV infusion (approximately 60 minutes) every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)
- Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Nagoya, Japan
Site not named
Osaka, Japan
Site not named
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.